NanoViricides Files Quarterly Report

The Company reported that it had $4.2 million in cash and cash
equivalents as of September 30th, 2009. The Company previously reported
that it had successfully raised a total of over $4.3M in different
private placement instruments. The details have been disclosed in an SEC
Form 8-K filed on October 5, 2009. The Company believes it has
sufficient funds to last through the end of December, 2010 at the
current rate of expenditure.

The Company now has four commercially important drugs in its pipeline,
targeting a total market size of approximately $40 Billion. These drugs
target HIV, all Influenzas, viral diseases of the external Eye, and
Herpes Simplex viral infections including cold sores and genital herpes
(HSV). In addition, the Company has R&D programs in collaborations with
reputed institutions against several Neglected Tropical Diseases and
agents of interest for Biosecurity. These include hemorrhagic fever
viruses such as Ebola/Marburg, Dengue, and Rabies, among others.

Our current drug programs include a pan-influenza drug candidate,
"FluCide(TM)". This drug was recently reported to be highly effective
against H1N1 influenza in a lethal animal model, leading to an average
14 days survival. It is generally believed that a 14 day survival in
this lethal challenge model would suggest indefinite survival in other
standardized animal models. FluCide is designed to be effective against
all influenza A strains and mutants. We anticipate FluCide to be
effective against highly pathogenic avian influenzas such as H7 and H9,
the epidemic bird flu virus H5N1 (various clades), the current novel
H1N1/2009 virus, seasonal influenza viruses, and their mutations.

The Company has previously reported that its anti-HIV drug candidate was
>25X (or >2,500%) more effective than the oral HAART treatment, on a
drug load basis. This study employed a standard SCID-hu Thy/Liv mouse
model. Human lymphocytes implanted in a mouse, and infected with HIV,
are treated with antiviral drugs in this model. It is very important to
note that no adverse events were observed in the nanoviricide treated
mice, while the HAART-treated mice exhibited clinical signs of side
effects. HAART or "highly active anti-retroviral therapy" is a
three-drug combination therapy currently in use in human clinical
practice, and is regarded as the most effective therapeutic regimen
against HIV. If these preliminary results are confirmed in further
animal studies and in human clinical trials, the Company believes that
HIVCide(TM) could very well result in a "Functional Cure" for HIV/AIDS.

The Company has reported significant progress in its topical
nanoviricide eye drops program. This drug is designed to treat most
viral infections of the external eye, including adenoviral epidemic
kerato-conjunctivitis (EKC) and herpes keratitis.

The Company also recently reported that it has successfully added a new
anti-HSV drug program to its pipeline this year. The Company's topical
anti-herpes drug candidate has already demonstrated greater than
10,000-fold (>99.99%, or >4 logs) reduction in virus quantity in cell
culture models of HSV-1 infection. Animal model studies of topical and
genital herpes are planned.

"We are now well poised to further develop our drug candidates with the
objective of filing an IND application as soon as possible," said Dr.
Eugene Seymour, MD, MPH, CEO of the Company.

About
NanoViricides:

NanoViricides,
Inc. (www.nanoviricides.com)
is a development stage company that is creating special purpose
nanomaterials for viral therapy. The Company's novel nanoviricide(TM) class
of drug candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs against
a number of viral diseases including H1N1 swine flu, H5N1 bird flu,
seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the
eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual events
could differ materially and substantially from those projected herein
and depend on a number of factors. Certain statements in this release,
and other written or oral statements made by NanoViricides, Inc. are
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act of
1934. You should not place undue reliance on forward-looking statements
since they involve known and unknown risks, uncertainties and other
factors which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no obligation
to publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if new
information becomes available in the future. Important factors that
could cause actual results to differ materially from the company's
expectations include, but are not limited to, those factors that are
disclosed under the heading "Risk Factors" and elsewhere in documents
filed by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although it is
not possible to predict or identify all such factors, they may include
the following: demonstration and proof of principle in pre-clinical
trials that a nanoviricide is safe and effective; successful development
of our product candidates; our ability to seek and obtain regulatory
approvals, including with respect to the indications we are seeking; the
successful commercialization of our product candidates; and market
acceptance of our products.

SOURCE: NanoViricides, Inc.

NanoViricides, Inc. 
Amanda Schuon, 310-550-7200 
info@nanoviricides.com

For full details on (NNVC) NNVC. (NNVC) has Short Term PowerRatings at TradingMarkets. Details on (NNVC) Short Term PowerRatings is available at This Link.

For full details on (NNVCE) NNVCE. (NNVCE) has Short Term PowerRatings at TradingMarkets. Details on (NNVCE) Short Term PowerRatings is available at This Link.